Krufton

Nilotinib, the active ingredient in Krufton, is a tyrosine kinase inhibitor presented as an oral tablet for oral administration. It selectively blocks the BCR‑ABL fusion protein, thereby inhibiting the uncontrolled proliferation of leukemic cells. The medication is used primarily in adult patients diagnosed with chronic myeloid leukemia. It is marketed in the European Union and meets stringent regulatory standards.

GNH USA supplies Krufton as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, providing reliable access to quality‑assured medicines for cancer care through a robust distribution network that ensures timely delivery.

Krufton (nilotinib) targets the BCR‑ABL driven pathway in chronic myeloid leukemia, providing disease control in patients who require a second‑generation tyrosine kinase inhibitor.

- Chronic myeloid leukemia (CML): reduces disease progression and improves survival in adult patients.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools often occurring early in therapy. - Rash: skin eruptions ranging from macular to papular. - Headache: transient mild to moderate pain. - Fatigue: general tiredness without specific cause. - Elevated liver enzymes: mild increases in transaminases.

Serious or Rare Side Effects: - QT interval prolongation: risk of ventricular arrhythmias. - Arterial occlusive events: including peripheral arterial disease. - Pancreatitis: inflammation of the pancreas with abdominal pain. - Severe hepatic injury: marked elevation of liver enzymes or bilirubin. - Severe neutropenia: marked reduction in neutrophil count. - Severe thrombocytopenia: low platelet counts leading to bleeding risk.

Patients should be monitored for specific safety concerns before and during treatment.

- Cardiovascular monitoring: obtain baseline ECG and repeat periodically to assess QT interval. - Liver function: check transaminases and bilirubin at regular intervals. - Pancreatic enzymes: monitor amylase and lipase for signs of pancreatitis. - Hematologic parameters: perform complete blood counts to detect cytopenias. - Drug interactions: avoid concomitant use of strong CYP3A4 inhibitors. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Nilotinib may interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase nilotinib exposure and toxicity. - QT‑prolonging agents (e.g., amiodarone, sotalol): heighten risk of arrhythmias. - Antacids containing aluminum or magnesium: reduce nilotinib absorption.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower nilotinib plasma levels. - Warfarin: may require more frequent INR monitoring. - St. John’s wort: can decrease nilotinib concentrations.